1 / 7

Development of New Biomarkers for Disease-Modifying Drugs in Alzheimer's Research

The Pharma-Cog initiative under the E-ADNI project aims to identify and develop novel biomarkers that can effectively assess the impact of symptomatic and disease-modifying drugs for Alzheimer's disease in both animal models and humans. The project focuses on creating reliable markers through comprehensive analyses including cognitive tests, MRI scans, blood samples, and other biological assessments. This research, funded by the Innovative Medicines Initiative, promotes collaboration between academia and the pharmaceutical industry to enhance drug development and improve outcomes for Alzheimer’s patients.

lapis
Télécharger la présentation

Development of New Biomarkers for Disease-Modifying Drugs in Alzheimer's Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADNI-relatedinitiatives in Europe: Pharma-Cog WP5 (E-ADNI) AIM: To develop new markers homologous in animal and humanssensitive to the effect of symptomatic and disease modifying drugs Disease- modifying drugs Development of markers in ANIMALS Development of markers in HUMANS Symptomatic drugs Development of markers in ANIMALS Development of markers in HUMANS

  2. Pharma-Cog Disease modifyingdrugssection WP5 WP6 75 MCI Ab42 pos. and 75 neg. Serial ass.t: 6 mos x 3 yrs ADNI cogn. tests ADNI struct MRI ADNI2 diffusion MRI, rest fMRI MR spectroscopy EEG & ERPs CSF & Blood Amyloid img (AZ ligand, others?) E-ADNI APP, APP/PS1, Tau, APP/Tau/PS2 mouse and lemur monkeys Serial ass.t: 3 mos x 2 yrs Homol. cogn. tests Homol. struct diff func MRI Homol. MR spectroscopy Homol. EEG & ERPs CSF & Blood Histology

  3. Pharma-Cog: partners Programs of peripheralbiomarkerdiscovery Takesactive part to design, statanalysis, etc.

  4. Pharma-Cog: timeschedule 2010 2011 2012 2013 2014 Literature review Data coll. prot.s IRB submissions Qualification Patient enrollment QC & QC enforcement Patient follow-up Data analysis

  5. Pharma-Cog: funding source IMI – Innovative Medicines Initiative: European Commission’s research scheme aimed to foster drug development by promoting academia-pharma (50-50) large joint research projects. 15 Funded so far: Alzheimer’s, Cancer, Diabetes (2), Pain, Depression & schizophrenia, Respiratory dis. (2), Basic pharmacology (7)

More Related